Characteristics of European Americans in DISCOVeRY-BMT GETH cohorts
| Category . | . | ||
|---|---|---|---|
| Cohort 1* (n = 2110) . | Cohort 2 (n = 777) . | GETH (n = 359) . | |
| Median age (range), y† | 45.3 (0.6-74.5) | 50 (0-74) | 45 (0-68) |
| Recipient sex | |||
| Male | 1191 (56.4) | 429 (55.2) | 225 (63) |
| Female | 919 (43.6) | 348 (44.8) | 134 (37) |
| Donor sex‡ | |||
| Male | 1396 (68) | 554 (72.6) | 201 (56) |
| Female | 656 (32) | 209 (27.4) | 158 (44) |
| Female donor/male recipient† | |||
| Yes | 332 (15.7) | 101 (13.0) | 91 (25) |
| No | 1778 (84.3) | 676 (87.0) | 268 (75) |
| Disease† | |||
| AML | 1282 (60.8) | 488 (62.8) | 116 (32) |
| ALL | 483 (22.9) | 94 (12.1) | 49 (13.5) |
| MDS§ | 345 (16.4) | 195 (25.1) | 34 (9.5) |
| Other‖ | 0 (0) | 0 (0) | 160 (44) |
| Stem cell source† | |||
| Peripheral blood | 1365 (64.7) | 567 (73) | 250 (69.6) |
| Bone marrow | 745 (35.3) | 210 (27) | 109 (30.4) |
| Conditioning intensity† | |||
| Myeloablative | 1540 (73) | 551 (71) | 253 (70) |
| Reduced intensity | 570 (27) | 225 (29) | 106 (30) |
| Conditioning regimen† | |||
| TBI | 973 (46.1) | 280 (36) | 94 (26) |
| No TBI | 1137 (53.9) | 497 (64) | 265 (74) |
| Outcome | |||
| Grade 2-4 aGVHD | 973 (46.1) | 358 (46.1) | 115 (32) |
| Grade 3-4 aGVHD | 389 (18.4) | 168 (21.6) | 50 (14) |
| NRM | 405 (19.2) | 141 (18.1) | 86 (24) |
| Category . | . | ||
|---|---|---|---|
| Cohort 1* (n = 2110) . | Cohort 2 (n = 777) . | GETH (n = 359) . | |
| Median age (range), y† | 45.3 (0.6-74.5) | 50 (0-74) | 45 (0-68) |
| Recipient sex | |||
| Male | 1191 (56.4) | 429 (55.2) | 225 (63) |
| Female | 919 (43.6) | 348 (44.8) | 134 (37) |
| Donor sex‡ | |||
| Male | 1396 (68) | 554 (72.6) | 201 (56) |
| Female | 656 (32) | 209 (27.4) | 158 (44) |
| Female donor/male recipient† | |||
| Yes | 332 (15.7) | 101 (13.0) | 91 (25) |
| No | 1778 (84.3) | 676 (87.0) | 268 (75) |
| Disease† | |||
| AML | 1282 (60.8) | 488 (62.8) | 116 (32) |
| ALL | 483 (22.9) | 94 (12.1) | 49 (13.5) |
| MDS§ | 345 (16.4) | 195 (25.1) | 34 (9.5) |
| Other‖ | 0 (0) | 0 (0) | 160 (44) |
| Stem cell source† | |||
| Peripheral blood | 1365 (64.7) | 567 (73) | 250 (69.6) |
| Bone marrow | 745 (35.3) | 210 (27) | 109 (30.4) |
| Conditioning intensity† | |||
| Myeloablative | 1540 (73) | 551 (71) | 253 (70) |
| Reduced intensity | 570 (27) | 225 (29) | 106 (30) |
| Conditioning regimen† | |||
| TBI | 973 (46.1) | 280 (36) | 94 (26) |
| No TBI | 1137 (53.9) | 497 (64) | 265 (74) |
| Outcome | |||
| Grade 2-4 aGVHD | 973 (46.1) | 358 (46.1) | 115 (32) |
| Grade 3-4 aGVHD | 389 (18.4) | 168 (21.6) | 50 (14) |
| NRM | 405 (19.2) | 141 (18.1) | 86 (24) |
Data are n (%) unless otherwise noted.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; TBI, total-body irradiation.
To be comparable to multivariate analysis in literature, for analysis of grade 2-4 aGVHD and grade 3-4 aGVHD, patients who died without grade 2-4 aGVHD or grade 3-4 aGVHD, respectively, within the 100 d were excluded. After exclusion, difference in number of patients between grade 2-4 aGVHD cohort and grade 3-4 aGVHD cohort was <0.6% in cohorts 1 and 2, so we did not include separate patient characteristics for grade 3-4 aGVHD cohort in table.
Tested in clinical models by Martínez-Laperche et al.1
There were 2052 donors in cohort 1 and 763 donors in cohort 2 for analysis of NRM, 1906 donors in cohort 1 and 698 donors in cohort 2 for analysis of grade 2-4 aGVHD II-IV, and 1894 donors in cohort 1 and 692 in cohort 2 for grade 3-4 aGVHD.
Includes MDS patients in DISCOVeRY-BMT and both MDS and myelofibrosis patients in GETH.
Other includes non-Hodgkin lymphoma, Hodgkin disease, multiple myeloma, chronic myeloid leukemia, and aplastic anemia.